Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping
- PMID: 40316478
- DOI: 10.1016/j.urolonc.2025.03.025
Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping
Abstract
Purpose: Frailty predicts adverse outcomes in bladder cancer (BC). Current guidelines endorse completion of Comprehensive Geriatric Assessments (CGAs) in older adults prior to treatment election to objectively measure frailty, however, these are rarely performed in urologic practice due to inadequate resources. We hypothesized CGA implementation would be feasible and identify multifaceted vulnerabilities beyond standard risk assessments in a multidisciplinary BC clinic and developed a novel method to visualize "vulnerability phenotypes" to guide supportive interventions.
Methods: Adults with BC were prospectively enrolled (June, 2020-July, 2021). Initially, patients underwent standard of care (SOC) risk assessment (N = 27). Subsequently, patients completed CGAs augmented with body composition assessments (N = 67). CGA completion time, rates, and patient-reported burden were assessed. Interdependence of CGA domains were quantified using Spearman correlation coefficients and compared decisional conflict and regret between arms. Vulnerability phenotypes were visualized using Spider Plots, generated in R. Clinical and survival associations with CGAs were evaluated using Cox proportional hazards models.
Results: 94 patients were enrolled with a median age of 72 years. Instrument completion in the CGA cohort was 79% to 100%. 91% of patients reported CGA completion was at most minimally burdensome. CGAs identified vulnerabilities including 31% vulnerable-to-moderately frail, 21% with mild-to-severe depression, 3% with mild-moderate dementia, and 40% at risk for malnutrition-malnourished. Frailty measures across instruments were weakly correlated (rho <0.4). In this heterogeneous cohort, vulnerability domains were not significantly associated with decisional conflict/regret, survival, nor complication rates after treatment. A novel Spider Plot tool is proposed to facilitate communication of the dominant vulnerability-driving individual risks.
Conclusions: CGAs can be successfully incorporated into uro-oncology practice with low perceived burden, identifying key vulnerabilities with implications for clinical care. Weak correlations across instruments support the value of gathering information across discrete domains. We present a novel approach to visually characterize personalized vulnerability phenotypes.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following potential conflicts of interest that may or may not appear to influence the work reported in this paper: Dana Cavanaugh has no disclosures. Sarah Holt has no disclosures. Erin Dwyer has no disclosures. Erin Petersen has no disclosures. John L. Gore is an advisor at Seagen Pharmaceuticals, Inc., and ImmunityBio. George R. Schade is a consultant at EDAP Technomed, an advisor at ImmunityBio, and has intellectual property licensed to Petal Surgical. Petros Grivas has provided consulting services for 4D Pharma, Aadi Bioscience, Abbvie, Astellas, Asieris Pharmaceuticals, AstraZeneca, BostonGene, Bristol Myers Squibb, CG Oncology, Dyania Health, Exelixis, Fresenius Kabi, Genentech, G1 Therapeutics, Gilead Sciences, Guardant Health, ImmunityBio, Infinity Pharmaceuticals, Janssen, Lucence, Merck KGaA, Mirati Therapeutics, MSD, Pfizer, PureTech, QED Therapeutics, Regeneron, Roche, Seattle Genetics, Silverback Therapeutics, Strata Oncology, and UroGen Pharma. He has received institutional research funding from Acrivon Therapeutics, ALX Oncology, Bavarian Nordic, Bristol Myers Squibb, Debiopharm Group, G1 Therapeutics, Genentech, Gilead Sciences, GlaxoSmithKline, Merck KGaA, Mirati Therapeutics, MSD, Pfizer, and QED Therapeutics. Andrew C. Hsieh has no disclosures. John Lee has no disclosures. Bruce Montgomery has no disclosures. Michael T. Schweizer is a paid consultant and/or has received honoraria from Sanofi, AstraZeneca, Janssen, Fibrogen, and Pfizer. He has received research funding to his institution from Novartis, Zenith Epigenetics, Eli Lilly, Bristol Myers Squibb, Merck, Immunomedics, Janssen, AstraZeneca, Pfizer, Hoffmann-La Roche, Tmunity, SignalOne Bio, Epigenetix, Xencor, Incyte, and Ambrx, Inc. Todd Yezefski has no disclosures. Evan Y. Yu has provided consulting services for Aadi Bioscience, Advanced Accelerator Applications, Bayer, Bristol Myers Squibb, Janssen, Loxo, Merck, and Oncternal. He has received research funding to his institution from Bayer, Blue Earth, Daiichi-Sankyo, Dendreon, Lantheus, Merck, Seagen, Surface, Taiho, and Tyra. Jonathan Chen has no disclosures. Jay J. Liao has no disclosures. Emily Weg has no disclosures. Jing Zeng has received research funding and served on an advisory board for AstraZeneca and IBA (Ion Beam Applications). Samia Jannat has no disclosures. Donna Berry has no disclosures. Viraj Master has no disclosures. Jose M. Garcia has no disclosures. May J. Reed has no disclosures. Itay Bentov has no disclosures. Jonathan Wright has received research funding from Merck, Seagen, Nucleix, Pacific Edge, Janssen, and Veracyte. He has provided consulting services for ImmunityBio and Pacific Edge and has received royalties from UptoDate. Sarah P. Psutka has provided consulting services for ImmunityBio, CG Oncology, and Janssen. She has received research funding from the NIA, Bladder Cancer Advocacy Network, Steba Biotech, and Janssen.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
